Does the media favor NERV or ESPR?

In the previous week, Esperion Therapeutics had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for Esperion Therapeutics and 1 mentions for Minerva Neurosciences. Esperion Therapeutics' average media sentiment score of 0.12 beat Minerva Neurosciences' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Esperion Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, NERV or OLMA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is NERV or OLMA more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% Olema Pharmaceuticals N/A -46.00% -41.22%

Which has better earnings and valuation, NERV or LBRX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A

Is NERV or LBRX more profitable?

Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% LB Pharmaceuticals N/A N/A N/A

Does the media prefer NERV or LBRX?

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for LB Pharmaceuticals and 1 mentions for Minerva Neurosciences. LB Pharmaceuticals' average media sentiment score of 0.24 beat Minerva Neurosciences' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LB Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SANA or NERV?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is SANA or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Minerva Neurosciences N/A N/A -32.63%

Which has stronger earnings and valuation, JBIO or NERV?

Jade Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$2.02 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is JBIO or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -51.34% -47.32% Minerva Neurosciences N/A N/A -32.63%

Minerva Neurosciences (NERV) Competitors

$4.38 +0.03 (+0.57%)

As of 12:52 PM Eastern

Compare

NERV vs. ESPR, OLMA, LBRX, SANA, and JBIO

Should you buy Minerva Neurosciences stock or one of its competitors? MarketBeat compares Minerva Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Minerva Neurosciences include Esperion Therapeutics (ESPR), Olema Pharmaceuticals (OLMA), LB Pharmaceuticals (LBRX), Sana Biotechnology (SANA), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry.

How does Minerva Neurosciences compare to Esperion Therapeutics?

Minerva Neurosciences (NASDAQ:NERV) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Minerva Neurosciences has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

In the previous week, Esperion Therapeutics had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for Esperion Therapeutics and 1 mentions for Minerva Neurosciences. Esperion Therapeutics' average media sentiment score of 0.12 beat Minerva Neurosciences' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Esperion Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Esperion Therapeutics has higher revenue and earnings than Minerva Neurosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Minerva Neurosciences' net margin of 0.00%. Minerva Neurosciences' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Minerva Neurosciences presently has a consensus price target of $10.50, suggesting a potential upside of 140.00%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 76.15%. Given Minerva Neurosciences' higher probable upside, equities analysts plainly believe Minerva Neurosciences is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Esperion Therapeutics beats Minerva Neurosciences on 9 of the 13 factors compared between the two stocks.

How does Minerva Neurosciences compare to Olema Pharmaceuticals?

Minerva Neurosciences (NASDAQ:NERV) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

In the previous week, Minerva Neurosciences had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Olema Pharmaceuticals. Minerva Neurosciences' average media sentiment score of 0.00 beat Olema Pharmaceuticals' score of -1.57 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Neutral
Olema Pharmaceuticals	Very Negative

Minerva Neurosciences has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Minerva Neurosciences presently has a consensus target price of $10.50, suggesting a potential upside of 140.00%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 281.22%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Minerva Neurosciences' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Summary

Olema Pharmaceuticals beats Minerva Neurosciences on 8 of the 13 factors compared between the two stocks.

How does Minerva Neurosciences compare to LB Pharmaceuticals?

Minerva Neurosciences (NASDAQ:NERV) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

34.6% of Minerva Neurosciences shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

Minerva Neurosciences presently has a consensus target price of $10.50, indicating a potential upside of 140.00%. LB Pharmaceuticals has a consensus target price of $38.40, indicating a potential upside of 21.04%. Given Minerva Neurosciences' higher possible upside, analysts clearly believe Minerva Neurosciences is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
LB Pharmaceuticals	N/A	N/A	N/A

In the previous week, LB Pharmaceuticals had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for LB Pharmaceuticals and 1 mentions for Minerva Neurosciences. LB Pharmaceuticals' average media sentiment score of 0.24 beat Minerva Neurosciences' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LB Pharmaceuticals beats Minerva Neurosciences on 9 of the 12 factors compared between the two stocks.

How does Minerva Neurosciences compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 175.76%. Minerva Neurosciences has a consensus price target of $10.50, suggesting a potential upside of 140.00%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Sana Biotechnology is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sana Biotechnology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Minerva Neurosciences' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Minerva Neurosciences	N/A	N/A	-32.63%

Sana Biotechnology has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market.

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Minerva Neurosciences had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Minerva Neurosciences	Neutral

Summary

Sana Biotechnology beats Minerva Neurosciences on 8 of the 12 factors compared between the two stocks.

How does Minerva Neurosciences compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

In the previous week, Minerva Neurosciences had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score.

Company	Overall Sentiment
Jade Biosciences	Neutral
Minerva Neurosciences	Neutral

Jade Biosciences currently has a consensus target price of $47.13, suggesting a potential upside of 109.58%. Minerva Neurosciences has a consensus target price of $10.50, suggesting a potential upside of 140.00%. Given Minerva Neurosciences' higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.6% of Minerva Neurosciences shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jade Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Minerva Neurosciences' return on equity of 0.00% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Minerva Neurosciences	N/A	N/A	-32.63%

Jade Biosciences has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market.

Summary

Jade Biosciences beats Minerva Neurosciences on 7 of the 13 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$203.79M	$3.00B	$6.55B	$12.20B
Dividend Yield	N/A	1.80%	2.69%	5.82%
P/E Ratio	-0.15	18.62	25.18	24.19
Price / Sales	N/A	483.91	554.67	122.21
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	-1.35	4.17	10.82	6.51
Net Income	-$293.42M	$64.45M	$3.56B	$337.14M
7 Day Performance	4.42%	2.31%	1.98%	0.26%
1 Month Performance	-16.83%	1.90%	1.43%	1.22%
1 Year Performance	140.91%	25.21%	31.13%	28.88%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NERV Minerva Neurosciences	2.1277 of 5 stars	$4.38 +0.6%	$10.50 +140.0%	+145.8%	$203.79M	N/A	N/A	9	News Coverage
ESPR Esperion Therapeutics	3.3512 of 5 stars	$3.16 +0.3%	$5.54 +75.3%	+203.8%	$814.31M	$418.24M	N/A	200	News Coverage
OLMA Olema Pharmaceuticals	1.9118 of 5 stars	$9.19 -7.0%	$44.10 +379.9%	+151.3%	$802.75M	N/A	N/A	70	Negative News
LBRX LB Pharmaceuticals	2.0628 of 5 stars	$27.66 -2.9%	$38.40 +38.8%	N/A	$793.29M	N/A	N/A	16	Analyst Upgrade
SANA Sana Biotechnology	1.8936 of 5 stars	$2.83 -0.7%	$9.50 +235.7%	+28.8%	$787.56M	N/A	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. ESPR, OLMA, LBRX, SANA, and JBIO

How does Minerva Neurosciences compare to Esperion Therapeutics?

Summary

How does Minerva Neurosciences compare to Olema Pharmaceuticals?

Summary

How does Minerva Neurosciences compare to LB Pharmaceuticals?

Summary

How does Minerva Neurosciences compare to Sana Biotechnology?

Summary

How does Minerva Neurosciences compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. ESPR, OLMA, LBRX, SANA, and JBIO

How does Minerva Neurosciences compare to Esperion Therapeutics?

Which has more volatility & risk, NERV or ESPR?

Does the media favor NERV or ESPR?

Do institutionals and insiders have more ownership in NERV or ESPR?

Which has stronger valuation and earnings, NERV or ESPR?

Is NERV or ESPR more profitable?

Do analysts rate NERV or ESPR?

Summary

How does Minerva Neurosciences compare to Olema Pharmaceuticals?

Do insiders & institutionals have more ownership in NERV or OLMA?

Which has preferable earnings and valuation, NERV or OLMA?

Does the media favor NERV or OLMA?

Which has more volatility and risk, NERV or OLMA?

Do analysts rate NERV or OLMA?

Is NERV or OLMA more profitable?

Summary

How does Minerva Neurosciences compare to LB Pharmaceuticals?

Do insiders and institutionals have more ownership in NERV or LBRX?

Which has better earnings and valuation, NERV or LBRX?

Do analysts recommend NERV or LBRX?

Is NERV or LBRX more profitable?

Does the media prefer NERV or LBRX?

Summary

How does Minerva Neurosciences compare to Sana Biotechnology?

Do analysts recommend SANA or NERV?

Which has higher valuation & earnings, SANA or NERV?

Is SANA or NERV more profitable?

Which has more volatility and risk, SANA or NERV?

Do institutionals and insiders believe in SANA or NERV?

Does the media refer more to SANA or NERV?

Summary

How does Minerva Neurosciences compare to Jade Biosciences?

Does the media refer more to JBIO or NERV?

Do analysts prefer JBIO or NERV?

Do institutionals & insiders believe in JBIO or NERV?

Which has stronger earnings and valuation, JBIO or NERV?

Is JBIO or NERV more profitable?

Which has more volatility & risk, JBIO or NERV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools